RT Journal Article
SR Electronic
T1 Outcomes of Persons With COVID-19 in Hospitals With and Without Standard Treatment With (Hydroxy)chloroquine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.14.20173369
DO 10.1101/2020.08.14.20173369
A1 EJG Peters
A1 D Collard
A1 S Van Assen
A1 M Beudel
A1 MK Bomers
A1 J Buijs
A1 LR De Haan
A1 W De Ruijter
A1 RA Douma
A1 PWG Elbers
A1 A Goorhuis
A1 NC Gritters van den Oever
A1 GHH Knarren
A1 HS Moeniralam
A1 RLM Mostard
A1 MJR Quanjel
A1 AC Reidinga
A1 R Renckens
A1 JPW Van Den Bergh
A1 IN Vlasveld
A1 JJ Sikkens
A1 On behalf of the CovidPredict Study Group
YR 2020
UL http://medrxiv.org/content/early/2020/08/15/2020.08.14.20173369.abstract
AB Objective To compare survival of subjects with COVID-19 treated in hospitals that either did or did not routinely treat patients with hydroxychloroquine or chloroquine.Methods We analysed data of COVID-19 patients treated in 9 hospitals in the Netherlands. Inclusion dates ranged from February 27th 2020, to May 15th, when the Dutch national guidelines no longer supported the use of (hydroxy)chloroquine. Seven hospitals routinely treated subjects with (hydroxy)chloroquine, two hospitals did not. Primary outcome was 21-day all-cause mortality. We performed a survival analysis using log-rank test and Cox-regression with adjustment for age, sex and covariates based on premorbid health, disease severity, and the use of steroids for adult respiratory distress syndrome, including dexamethasone.Results Among 1893 included subjects, 21-day mortality was 23.4% in 1552 subjects treated in hospitals that routinely prescribed (hydroxy)chloroquine, and 17.0% in 341 subjects that were treated in hospitals that did not. In the adjusted Cox-regression models this difference disappeared, with an adjusted hazard ratio of 1.17 (95%CI 0.88-1.55). When stratified by actually received treatment in individual subjects, the use of (hydroxy)chloroquine was associated with an increased 21-day mortality (HR 1.58; 95%CI 1.25-2.01) in the full model.Conclusions After adjustment for confounders, mortality was not significantly different in hospitals that routinely treated patients with (hydroxy)chloroquine, compared with hospitals that did not. We compared outcomes of hospital strategies rather than outcomes of individual patients to reduce the chance of indication bias. This study adds evidence against the use of (hydroxy)chloroquine in patients with COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding has been received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:METc VUmc, Amsterdam, the NetherlandsAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author, upon reasonable request.